2006 a vintage year for investment in Danish biotech  

With a record amount of venture capital flowing in, the Danish biotech industry delivered a robust investment performance in 2006
Danish biotech delivered a robust investment performance in 2006. In the nine months to September, Medicon Valley based biotech companies raised EUR 309 bn (USD 410 bn), compared with EUR 278 bn (USD 361 bn) for the whole of 2005. This reflects a maturing biotech industry where many pipeline projects have entered clinical trials, bringing them closer to the market and making them more attractive to investors.

Henrik Ernø, vice president of corporate finance at Danske Markets, comments: “In the last 24 months DKK 2.4 bn (USD 418 m) has been raised and in the last 18 months there were 3 IPOs. This has boosted awareness and interest in the biotech sector, making Copenhagen Stock Exchange one of the best European choices for an IPO.” Only Zurich offers comparable performance.

The venture capital environment is also buoyant. An analysis from Vækstfonden in November 2006 showed that in Q1-3 2006 venture investments grew 12% compared to 2005, outperforming the rest of the EU as well as the US. The analysis also revealed growing interest in Danish companies from international investors. In 2006 foreign investors were involved in 50% of venture investments, compared with 38% in 2005. The news was reported in a press release from Medicon Valley Academy.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×